- Home
- MSGE vs GLPG Comparison
MSGE vs GLPG Comparison
Compare MSGE & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGE
- GLPG
- Stock Information
- Founded
- MSGE 2020
- GLPG 1999
- Country
- MSGE United States
- GLPG Belgium
- Employees
- MSGE N/A
- GLPG N/A
- Industry
- MSGE Services-Misc. Amusement & Recreation
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- MSGE Consumer Discretionary
- GLPG Health Care
- Exchange
- MSGE Nasdaq
- GLPG Nasdaq
- Market Cap
- MSGE 1.9B
- GLPG 2.1B
- IPO Year
- MSGE N/A
- GLPG 2005
- Fundamental
- Price
- MSGE $39.25
- GLPG $31.44
- Analyst Decision
- MSGE Strong Buy
- GLPG Sell
- Analyst Count
- MSGE 5
- GLPG 4
- Target Price
- MSGE $50.20
- GLPG $25.33
- AVG Volume (30 Days)
- MSGE 328.8K
- GLPG 345.0K
- Earning Date
- MSGE 08-13-2025
- GLPG 07-23-2025
- Dividend Yield
- MSGE N/A
- GLPG N/A
- EPS Growth
- MSGE N/A
- GLPG N/A
- EPS
- MSGE 0.77
- GLPG N/A
- Revenue
- MSGE $942,734,000.00
- GLPG $323,674,692.00
- Revenue This Year
- MSGE $8.62
- GLPG N/A
- Revenue Next Year
- MSGE $4.69
- GLPG N/A
- P/E Ratio
- MSGE $50.64
- GLPG N/A
- Revenue Growth
- MSGE N/A
- GLPG 5.43
- 52 Week Low
- MSGE $28.29
- GLPG $22.36
- 52 Week High
- MSGE $44.14
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- MSGE 55.50
- GLPG 47.00
- Support Level
- MSGE $36.67
- GLPG $31.39
- Resistance Level
- MSGE $37.73
- GLPG $32.43
- Average True Range (ATR)
- MSGE 1.24
- GLPG 0.77
- MACD
- MSGE 0.17
- GLPG -0.22
- Stochastic Oscillator
- MSGE 75.92
- GLPG 7.22
About MSGE Madison Square Garden Entertainment Corp.
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.